{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:22:41Z","timestamp":1776770561806,"version":"3.51.2"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,13]]},"DOI":"10.7759\/cureus.45169","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T17:23:58Z","timestamp":1694625838000},"source":"Crossref","is-referenced-by-count":2,"title":["Predictors of Pharmacy Students' Attitudes About the Therapeutic Use of Psilocybin"],"prefix":"10.7759","author":[{"given":"NM Mahmudul Alam","family":"Bhuiya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin J","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiqun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Nava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke","family":"Sampiere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akhila","family":"Yerubandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s40345-022-00265-5","article-title":"Psychedelics in the treatment of unipolar and bipolar depression","volume":"10","author":"Bosch OG","year":"2022","unstructured":"Bosch OG, Halm S, Seifritz E. Psychedelics in the treatment of unipolar and bipolar depression. Int J Bipolar Disord. 2022, 10:18. 10.1186\/s40345-022-00265-5","journal-title":"Int J Bipolar Disord"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2017.01.024","article-title":"Clinical potential of psilocybin as a treatment for mental health conditions","volume":"7","author":"Daniel J","year":"2017","unstructured":"Daniel J, Haberman M. Clinical potential of psilocybin as a treatment for mental health conditions. Ment Health Clin. 2017, 7:24-8. 10.9740\/mhc.2017.01.024","journal-title":"Ment Health Clin"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21944","article-title":"Analysis of psilocybin-assisted therapy in medicine: a narrative review","volume":"14","author":"Ziff S","year":"2022","unstructured":"Ziff S, Stern B, Lewis G, Majeed M, Gorantla VR. Analysis of psilocybin-assisted therapy in medicine: a narrative review. Cureus. 2022, 14:e21944. 10.7759\/cureus.21944","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols DE","year":"2016","unstructured":"Nichols DE. Psychedelics. Pharmacol Rev. 2016, 68:264-355. 10.1124\/pr.115.011478","journal-title":"Pharmacol Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0542-y","article-title":"Potential therapeutic effects of psilocybin","volume":"14","author":"Johnson MW","year":"2017","unstructured":"Johnson MW, Griffiths RR. Potential therapeutic effects of psilocybin. Neurotherapeutics. 2017, 14:734-40. 10.1007\/s13311-017-0542-y","journal-title":"Neurotherapeutics"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26102948","article-title":"The therapeutic potential of psilocybin","volume":"26","author":"Lowe H","year":"2021","unstructured":"Lowe H, Toyang N, Steele B, et al.. The therapeutic potential of psilocybin. Molecules. 2021, 26:2948. 10.3390\/molecules26102948","journal-title":"Molecules"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis AK","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, et al.. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021, 78:481-9. 10.1001\/jamapsychiatry.2020.3285","journal-title":"JAMA Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.31796","article-title":"Psilocybin as a treatment for psychiatric illness: a meta-analysis","volume":"14","author":"Irizarry R","year":"2022","unstructured":"Irizarry R, Winczura A, Dimassi O, Dhillon N, Minhas A, Larice J. Psilocybin as a treatment for psychiatric illness: a meta-analysis. Cureus. 2022, 14:e31796. 10.7759\/cureus.31796","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross S","year":"2016","unstructured":"Ross S, Bossis A, Guss J, et al.. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016, 30:1165-80. 10.1177\/0269881116675512","journal-title":"J Psychopharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin GM","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, et al.. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022, 387:1637-48. 10.1056\/NEJMoa2206443","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3109\/14659890903271624","article-title":"User perceptions of the benefits and harms of hallucinogenic drug use: a web-based questionnaire study","volume":"15","author":"Carhart-Harris RL","year":"2010","unstructured":"Carhart-Harris RL, Nutt DJ. User perceptions of the benefits and harms of hallucinogenic drug use: a web-based questionnaire study. J Subst Use. 2010, 15:283-300. 10.3109\/14659890903271624","journal-title":"J Subst Use"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211073759","article-title":"Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up","volume":"36","author":"Gukasyan N","year":"2022","unstructured":"Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, Griffiths RR. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. J Psychopharmacol. 2022, 36:151-8. 10.1177\/02698811211073759","journal-title":"J Psychopharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz MP","year":"2015","unstructured":"Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015, 29:289-99. 10.1177\/0269881114565144","journal-title":"J Psychopharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson M","year":"2008","unstructured":"Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008, 22:603-20. 10.1177\/0269881108093587","journal-title":"J Psychopharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2012.04.002","article-title":"Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies","volume":"35","author":"Ross S","year":"2012","unstructured":"Ross S. Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies. Psychiatr Clin North Am. 2012, 35:357-74. 10.1016\/j.psc.2012.04.002","journal-title":"Psychiatr Clin North Am"},{"key":"ref16","unstructured":"Controlled substance schedule. (2023). Accessed. August 5, 2023: https:\/\/www.deadiversion.usdoj.gov\/schedules\/."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05719-1","article-title":"Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants","volume":"238","author":"Galv\u00e3o-Coelho NL","year":"2021","unstructured":"Galv\u00e3o-Coelho NL, Marx W, Gonzalez M, Sinclair J, de Manincor M, Perkins D, Sarris J. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology (Berl). 2021, 238:341-54. 10.1007\/s00213-020-05719-1","journal-title":"Psychopharmacology (Berl)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-021-01150-y","article-title":"The evolution of the psychedelic revolution","volume":"47","author":"Cameron LP","year":"2022","unstructured":"Cameron LP, Olson DE. The evolution of the psychedelic revolution. Neuropsychopharmacology. 2022, 47:413-4. 10.1038\/s41386-021-01150-y","journal-title":"Neuropsychopharmacology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.4101","article-title":"Psychedelic drug legislative reform and legalization in the US","volume":"80","author":"Siegel JS","year":"2023","unstructured":"Siegel JS, Daily JE, Perry DA, Nicol GE. Psychedelic drug legislative reform and legalization in the US. JAMA Psychiatry. 2023, 80:77-83. 10.1001\/jamapsychiatry.2022.4101","journal-title":"JAMA Psychiatry"},{"key":"ref20","unstructured":"FDA grants breakthrough therapy designation for MDMA-assisted therapy for PTSD, agrees on special protocol assessment for phase 3 trials. (2022). Accessed. August 5, 2023: https:\/\/maps.org\/news\/media\/press-release-fda-grants-breakthrough-therapy-designation-for-mdma-assisted-psychotherapy...."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115598338","article-title":"Psilocybin, psychological distress, and suicidality","volume":"29","author":"Hendricks PS","year":"2015","unstructured":"Hendricks PS, Johnson MW, Griffiths RR. Psilocybin, psychological distress, and suicidality. J Psychopharmacol. 2015, 29:1041-3. 10.1177\/0269881115598338","journal-title":"J Psychopharmacol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-021-00889-x","article-title":"Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies","volume":"20","author":"Niles H","year":"2021","unstructured":"Niles H, Fogg C, Kelmendi B, Lazenby M. Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies. BMC Palliat Care. 2021, 20:191. 10.1186\/s12904-021-00889-x","journal-title":"BMC Palliat Care"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris RL","year":"2018","unstructured":"Carhart-Harris RL, Bolstridge M, Day CM, et al.. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). 2018, 235:399-408. 10.1007\/s00213-017-4771-x","journal-title":"Psychopharmacology (Berl)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-021-00489-1","article-title":"Ethical and legal issues in psychedelic harm reduction and integration therapy","volume":"18","author":"Pilecki B","year":"2021","unstructured":"Pilecki B, Luoma JB, Bathje GJ, Rhea J, Narloch VF. Ethical and legal issues in psychedelic harm reduction and integration therapy. Harm Reduct J. 2021, 18:40. 10.1186\/s12954-021-00489-1","journal-title":"Harm Reduct J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.37450","article-title":"Predictors of medical students' perceptions of psilocybin-assisted therapy for use in medical practice","volume":"15","author":"Wang K","year":"2023","unstructured":"Wang K, Sun Y, Nava B, Sampiere L, Jacobs RJ. Predictors of medical students' perceptions of psilocybin-assisted therapy for use in medical practice. Cureus. 2023, 15:e37450. 10.7759\/cureus.37450","journal-title":"Cureus"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1190507","article-title":"Medical student attitudes and perceptions of psychedelic-assisted therapies","volume":"14","author":"Li I","year":"2023","unstructured":"Li I, Fong R, Hagen M, Tabaac B. Medical student attitudes and perceptions of psychedelic-assisted therapies. Front Psychiatry. 2023, 14:1190507. 10.3389\/fpsyt.2023.1190507","journal-title":"Front Psychiatry"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18158160","article-title":"Cancer healthcare workers' perceptions toward psychedelic-assisted therapy: a preliminary investigation","volume":"18","author":"Reynolds LM","year":"2021","unstructured":"Reynolds LM, Akroyd A, Sundram F, Stack A, Muthukumaraswamy S, Evans WJ. Cancer healthcare workers' perceptions toward psychedelic-assisted therapy: a preliminary investigation. Int J Environ Res Public Health. 2021, 18:8160. 10.3390\/ijerph18158160","journal-title":"Int J Environ Res Public Health"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2022.114727","article-title":"Magic mushrooms - an exploratory look at how mental health professionals feel and think about psilocybin","volume":"316","author":"Meyer TD","year":"2022","unstructured":"Meyer TD, Meir P, Lex C, Soares JC. Magic mushrooms - an exploratory look at how mental health professionals feel and think about psilocybin. Psychiatry Res. 2022, 316:114727. 10.1016\/j.psychres.2022.114727","journal-title":"Psychiatry Res"},{"key":"ref29","article-title":"Pharmacists\u2019 experience, knowledge, attitudes, and perspectives of psilocybin in Canada","author":"Sugiarto E","year":"2023","unstructured":"Sugiarto E, Yuen J. Pharmacists\u2019 experience, knowledge, attitudes, and perspectives of psilocybin in Canada. American Pharmacists Association 2023 Annual Meeting and Exposition. American Pharmacists Association, Washington, DC; 2023."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1177\/08971900221096969","article-title":"Pharmacy students\u2019 knowledge, attitudes, and awareness toward marijuana use. [PREPRINT]","author":"Hasan KM","year":"2022","unstructured":"Hasan KM, Oluwafemi O, Ketchatang W. Pharmacy students\u2019 knowledge, attitudes, and awareness toward marijuana use. [PREPRINT]. J Pharm Pract. 2022, 10.1177\/08971900221096969","journal-title":"J Pharm Pract"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.7416\/ai.2019.2264","article-title":"The pharmacist's role in health information, vaccination and health promotion","volume":"31","author":"Petrelli F","year":"2019","unstructured":"Petrelli F, Tiffi F, Scuri S, Nguyen CTT, Grappasonni I. The pharmacist's role in health information, vaccination and health promotion. Ann Ig. 2019, 31:309-15. 10.7416\/ai.2019.2264","journal-title":"Ann Ig"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.24390","article-title":"Predictors of medical students' perceptions about medical cannabis","volume":"14","author":"Jacobs RJ","year":"2022","unstructured":"Jacobs RJ, Kane MN, Caballero J. Predictors of medical students' perceptions about medical cannabis. Cureus. 2022, 14:e24390. 10.7759\/cureus.24390","journal-title":"Cureus"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28336","article-title":"Medical students\u2019 attitudes, knowledge, and beliefs about medical cannabis: a qualitative descriptive study","volume":"14","author":"Jacobs RJ","year":"2022","unstructured":"Jacobs RJ, Colon J, Kane MN. Medical students\u2019 attitudes, knowledge, and beliefs about medical cannabis: a qualitative descriptive study. Cureus. 2022, 14:e28336. 10.7759\/cureus.28336","journal-title":"Cureus"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.25749","article-title":"Exploratory factor analysis of medical students' perceptions of medical cannabis scale","volume":"14","author":"Jacobs RJ","year":"2022","unstructured":"Jacobs RJ, Kane MN. Exploratory factor analysis of medical students' perceptions of medical cannabis scale. Cureus. 2022, 14:e25749. 10.7759\/cureus.25749","journal-title":"Cureus"},{"key":"ref35","unstructured":"IBM SPSS Statistics for Windows. (2023). Accessed. June 13, 2023: https:\/\/www.ibm.com\/products\/spss-statistics."},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris PA","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009, 42:377-81. 10.1016\/j.jbi.2008.08.010","journal-title":"J Biomed Inform"},{"key":"ref37","article-title":"Psychometric Theory","author":"Nunnally JC","year":"1978","unstructured":"Nunnally JC. Psychometric Theory. McGraw-Hill, New York, NY; 1978."},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216556","article-title":"Health professional beliefs, knowledge, and concerns surrounding medicinal cannabis - a systematic review","volume":"14","author":"Gardiner KM","year":"2019","unstructured":"Gardiner KM, Singleton JA, Sheridan J, Kyle GJ, Nissen LM. Health professional beliefs, knowledge, and concerns surrounding medicinal cannabis - a systematic review. PLoS One. 2019, 14:e0216556. 10.1371\/journal.pone.0216556","journal-title":"PLoS One"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/179779-predictors-of-pharmacy-students-attitudes-about-the-therapeutic-use-of-psilocybin","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:06:05Z","timestamp":1707509165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/179779-predictors-of-pharmacy-students-attitudes-about-the-therapeutic-use-of-psilocybin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.45169","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,13]]}}}